Targeting Polypeptide Magnetic Nanoparticles for CTC Molecular Typing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional tumor detection methods, such as imaging and tissue biopsy, struggle to accurately detect small tumors and provide molecular typing for personalized treatment, while existing CTC detection methods lack sensitivity and specificity for biomarker analysis.
Innovation Solution
A polypeptide magnetic nanoparticle comprising a specific targeting polypeptide and magnetic nanoparticle, designed to capture and analyze circulating tumor cells (CTCs) for molecular typing, using a method that includes preparing a polypeptide and magnetic nanoparticle solution, mixing them, and applying the mixture to patient samples for detection and analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging and tissue biopsy methods are used for tumor detection, then the detection process is simple and well-established, but the resolution is insufficient to detect tumors less than 5 mm and molecular typing capability is limited
Solution Approach 1:
The patent employs a composite detection system consisting of magnetic nanoparticles functionalized with specific antibodies (such as anti-HER2, anti-ER, anti-PR antibodies) combined with circulating tumor cells (CTCs) isolated from patient blood samples. This composite approach enables simultaneous detection of multiple tumor markers and molecular typing, achieving high sensitivity for tumors less than 5 mm while providing comprehensive molecular characterization for personalized treatment guidance
Solution Approach 2:
The patent uses magnetic nanoparticles as intermediary carriers that bind to specific tumor markers on CTCs. These nanoparticle-CTC complexes serve as intermediaries that concentrate rare tumor cells from large blood volumes, enabling sensitive detection and molecular analysis. The magnetic properties of the nanoparticles allow for easy separation and concentration of target cells using magnetic fields, significantly improving detection sensitivity
2Measurement precision
If tissue biopsy is performed for molecular typing, then molecular diagnosis can be achieved, but the procedure is invasive and cannot achieve multiple sampling
Solution Approach 1:
The patent detects and analyzes circulating tumor cells (CTCs) that are naturally shed from the primary tumor into the bloodstream. These CTCs serve as living copies carrying the same genetic and protein information as the original tumor tissue. By analyzing these circulating copies through immunofluorescence staining for markers like HER2, ER, PR, and PD-L1, the patent achieves accurate molecular typing without requiring invasive tissue biopsy, thereby eliminating patient pain and procedural risks while enabling repeated sampling over time
3Ease of operation
If traditional pathological classification is used for tumor diagnosis, then the classification process is straightforward, but the ability to predict tumor behavior and treatment response is limited
Solution Approach 1:
The patent employs a multi-functional detection platform that simultaneously evaluates multiple molecular markers (HER2, ER, PR, PD-L1, EGFR, AR) on the same CTC sample. This universal approach provides comprehensive molecular profiling including hormone receptor status, HER2 amplification, and immune checkpoint expression, enabling prediction of responses to various treatments such as hormone therapy, targeted therapy, and immunotherapy. The system maintains operational simplicity through automated immunofluorescence staining and image analysis while capturing extensive molecular information that traditional single-marker methods miss
Data Source
AI summary
Described is a polypeptide magnetic nanoparticle having a specific targeting polypeptide and a magnetic nanoparticle. The amino acid sequence of the specific targeting polypeptide is VRRDAPRFSMQGLDA-X, and the C-terminal X thereof is a sequence of 5 to 20 amino acids. The amino acid in the amino acid sequence of C-terminal X is selected from one or more of: C, G, and N. The polypeptide magnetic nanoparticle can be used for CTC detection and molecular typing of various cancer types, including esophageal cancer, liver cancer, lung cancer, stomach cancer, bladder cancer, skin cancer, melanoma, breast cancer, colorectal cancer, cervical cancer, etc. Biomarkers of CTC molecular typing include PD-L1, HER2, ER, PR, AR, EGFR, VEGFR, CXCR4, etc. The polypeptide magnetic nanoparticle is helpful for CTC detection and the qualitative and semiquantitative analysis of expression levels of biomarkers at CTC level, thereby performing precise therapy such as targeted individualized targeted therapy or immunotherapy on patients.